FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP
• ==					• • • • • • • • • • • • • • • • • • • •

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Schwartz Jonathan David (Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE					- RO	2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. [RCKT] 3. Date of Earliest Transaction (Month/Day/Year) 02/01/2021								(Chec	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer					
(Street) CRANB (City)	URY N	J tate)	08512 (Zip)	n-Deriv	-	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Fi Line) X Form filed by One R Form filed by More t Person ative Securities Acquired, Disposed of, or Beneficially Owned								Repo	rting Person					
1. Title of Security (Instr. 3) 2. Transc Date				sactio			3. 4. Securiting Disposed Code (Instr.		ities Acqu	red (A)) or	5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Cod	e v	Amount	(A) (D)	or F	Price	Transacti (Instr. 3 a	ion(s)					
Common Stock 02			02/0	01/202	1/2021		М		11,42	11,428 A		\$1.69	11,428			D				
Common Stock 02/0			02/0	01/202	/2021		М		213,1	213,101 A		\$1.21	224,529			D				
(e.g., p 1. Title of						nsaction Derivative E			6. Date Expirati						8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis		Expiration Date	Title	or Num	ount nber hares		Transaction (Instr. 4)				
Stock Option (Right to Buy)	\$1.69	02/01/2021			D			11,428	(1)		04/12/2027	Commo	11,	,428	\$0	0		D		
Stock Option (Right to Buy)	\$1.21	02/10/2020			D			213,101	(2)		02/08/2026	Commo: Stock	213	3,101	\$0	38,309	9	D		

Explanation of Responses:

- 1. This option represents a right to purchase a total of 11,428 shares of the Issuer's Common Stock 4,113 of which will become fully vested and exercisable on April 12, 2018, with the remaining 7,315 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
- 2. This option represents a right to purchase a total of 251,410 shares of the Issuer's Common Stock 83,803 of which became fully vested and exercisable on February 8, 2017, with the remaining 167,607 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

/s/ Sara Turken, as attorney-in-02/03/2021 fact for Jonathan Schwartz

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.